A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern Cooperative Oncology Group study

Barbara A. Burtness, J. Manola, R. Axelrod, A. Argiris, A. A. Forastiere

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Fingerprint Dive into the research topics of 'A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern Cooperative Oncology Group study'. Together they form a unique fingerprint.

Medicine & Life Sciences